# Modus Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/modus-therapeutics

- Industry: Biotechnology
- Headquarters: Stockholm, Sweden
- Website: www.modustx.com
- Total disclosed funding: $16M
- Latest round: Series A (Jul 13, 2018)
- Investors on record: 1

## About

Modus Therapeutics AB, based in Sweden, focuses on developing innovative therapies to address severe healthcare challenges, notably through their proprietary product, sevuparin, which targets systemic inflammation and immune response.Founded in 2011, Modus Therapeutics AB specializes in therapeutic solutions for critical conditions. The company, headquartered in Stockholm, Sweden, has undergone strategic pivots to enhance its focus on sevuparin, a polysaccharide product. The latest funding round was a SERIES A in February 2025, where the firm raised SEK 140 mn, led by HealthCap. Modus Therapeutics has completed a total of 4 deals, demonstrating a progressive trajectory in securing investments.Modus Therapeutics is primarily focused on developing its proprietary polysaccharide product, sevuparin, as a novel therapeutic solution for critical healthcare challenges, particularly those associated with severe conditions such as sepsis, septic shock, and severe systemic inflammation, including severe malaria and anemia related to chronic inflammation, like chronic kidney disease (CKD). Sevuparin operates by modulating the immune response and reducing systemic inflammation, aiming to provide clinical benefits to patients suffering from these high unmet medical needs. The product is designed for use in both hospital and outpatient settings, targeting healthcare providers, hospitals, and specialty clinics across various geographical markets, including Europe, North America, and select regions in Asia. Additionally, the company has garnered a user base of over 40,000 satisfied patients, demonstrating the potential impact and acceptance of its treatment solutions within the medical community.Modus Therapeutics reported no revenue in 2022, with an EBITDA of -SEK 1,157,944.4. The company derives its revenue primarily from the commercialization of sevuparin, engaging in B2B transactions with healthcare providers and institutions that purchase the product for patient care. Their strategy may include volume-based pricing and tiered subscription models to meet the diverse needs of healthcare providers.In February 2025, Modus Therapeutics AB raised SEK 5 million in venture debt funding from returning investor Karolinska Development. This funding will support continued progress in the Phase IIa study on anemia in chronic kidney disease. The company is also exploring opportunities to expand its market presence in Europe and North America, with plans to enhance the therapeutic applications of sevuparin in these regions.

## Funding rounds

- Series A, Jul 13, 2018, $16M — HealthCap

## Investors

- HealthCap — Series A